Stay updated on BL-8040/Pembrolizumab Combo in Pancreatic Cancer Clinical Trial
Sign up to get notified when there's something new on the BL-8040/Pembrolizumab Combo in Pancreatic Cancer Clinical Trial page.

Latest updates to the BL-8040/Pembrolizumab Combo in Pancreatic Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has been updated to include the study's new revision number (v2.15.0) and the name of the study chair, Abi Vainstein, MD, while significant details about the study's design and treatment protocols have been removed.SummaryDifference49%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.9%
- Check87 days agoChange DetectedThe page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference0.9%
Stay in the know with updates to BL-8040/Pembrolizumab Combo in Pancreatic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the BL-8040/Pembrolizumab Combo in Pancreatic Cancer Clinical Trial page.